Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Open-Label Multicenter Study to Assess the Diagnostic Performance of Piflufolastat F 18 PET/CT on Intended Clinical Management in Patients With Suspected, or at High Risk for Metastatic ccRCC

NCT07084909 is registered in ClinicalTrials.gov with Lantheus Medical Imaging as lead sponsor.

NCT NCT07084909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07084909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Open-Label Multicenter Study to Assess the Diagnostic Performance of Piflufolastat F 18 PET/CT on Intended Clinical Management in Patients With Suspected, or at High Risk for Metastatic ccRCC
Lead sponsor
Lantheus Medical Imaging
Phase
Phase 2/3
Overall status
Withdrawn
Start date
November 30, 2025
Completion date
September 30, 2027
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma